Xospata, Astellas
Gilteritinib Effective for Relapsed/Refractory FLT3-Mutated AML
Findings from the randomized, phase 3 ADMIRAL study have found the FLT3 inhibitor gilteritinib (Xospata, Astellas) ...
NOVEMBER 25, 2019
Phase 3 Trial Supports Value of Gilteritinib for FLT3-Positive Relapsed or Refractory AML
The selective FLT3 inhibitor gilteritinib (Xospata, Astellas) led to significantly longer overall survival, higher ...
APRIL 23, 2019
Load more